• Publications
  • Influence
Horse versus rabbit antithymocyte globulin in acquired aplastic anemia.
BACKGROUND In severe acquired aplastic anemia, hematopoietic failure is the result of immune-mediated destruction of bone marrow stem and progenitor cells. Immunosuppressive therapy withExpand
  • 327
  • 33
  • PDF
Antithymocyte globulin and cyclosporine for severe aplastic anemia: association between hematologic response and long-term outcome.
CONTEXT In most patients, aplastic anemia results from T-cell-mediated immune destruction of bone marrow. Aplastic anemia can be effectively treated by stem cell transplantation or immunosuppression.Expand
  • 317
  • 18
  • PDF
Mutations of the human telomerase RNA gene (TERC) in aplastic anemia and myelodysplastic syndrome.
Mutations in the human telomerase RNA (TERC) occur in autosomal dominant dyskeratosis congenita (DKC). Because of the possibility that TERC mutations might underlie seemingly acquired forms of boneExpand
  • 280
  • 12
Retreatment with rabbit anti‐thymocyte globulin and ciclosporin for patients with relapsed or refractory severe aplastic anaemia
The management of patients with severe aplastic anaemia (SAA) who do not have a matched sibling donor and fail a course of horse anti‐thymocyte globulin (h‐ATG)/ciclosporin (CsA) is uncertain.Expand
  • 146
  • 12
Activity of alemtuzumab monotherapy in treatment-naive, relapsed, and refractory severe acquired aplastic anemia.
Antithymocyte globulin (ATG) + cyclosporine is effective in restoring hematopoiesis in severe aplastic anemia (SAA). We hypothesized that the humanized anti-CD52 mAb alemtuzumab might be active inExpand
  • 93
  • 10
Distinct clinical outcomes for cytogenetic abnormalities evolving from aplastic anemia.
A serious complication of aplastic anemia (AA) is its evolution to clonal hematologic diseases such as myelodysplasia (MDS) and leukemia, which is usually associated with the appearance of aExpand
  • 210
  • 9
Cytokine signature profiles in acquired aplastic anemia and myelodysplastic syndromes
Although aplastic anemia and myelodysplasia have been extensively investigated, little is known about their circulating cytokine patterns. We compared plasma soluble cytokines in 33 aplastic anemia,Expand
  • 94
  • 8
  • PDF
Predicting response to immunosuppressive therapy and survival in severe aplastic anaemia
Horse anti‐thymocyte globulin (h‐ATG) and ciclosporin are the initial therapy for most patients with severe aplastic anaemia (SAA), but there is no practical and reliable method to predict responseExpand
  • 165
  • 6
Treatment of severe aplastic anaemia with combined immunosuppression: anti‐thymocyte globulin, ciclosporin and mycophenolate mofetil
Severe aplastic anaemia (SAA) can be successfully treated with immunosuppressive therapies or haematopoietic stem cell transplantation (HSCT). Response rates with horse anti‐thymocyte globulinExpand
  • 125
  • 6
Long-term outcome of pediatric patients with severe aplastic anemia treated with antithymocyte globulin and cyclosporine.
OBJECTIVE To determine the long-term outcomes in children with severe aplastic anemia (SAA) treated with antithymocyte globulin (ATG) and cyclosporine (CsA) through a retrospective analysis of theExpand
  • 99
  • 5